Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma

Bendamustine (Treanda, Ribomustin) was recently approved by the US Food and Drug Administration (FDA) for treatment of patients with rituximab refractory indolent lymphoma and is expected to turn into a frontline therapy option for indolent lymphoma. This compound with amphoteric properties was designed in the former Germany Democratic Republic in 1960s and re-discovered in 1990s with multiple successive well-designed studies. Bendamustine possesses a unique mechanism of action with potential antimetabolite properties, and only partial cross-resistance with other alkylators. Used in combination with rituximab in vitro, bendamustine shows synergistic effects against various leukemia and lymphoma cell lines. In clinical studies, bendamustine plus rituximab is highly effective in patients with relapsed-refractory indolent lymphoma, inducing remissions in 90% or more and a median progression-free survival of 23–24 months. The optimal dosing and schedule of bendamustine administration is largely undecided and varies among studies. Results of ongoing trials and dose-finding studies will help to further help ascertain the optimal place of bendamustine in the management of indolent NHL

NetzWerk LebenPlus (NWLP) - ein Hilfs- und Betreuungsnetzwerk für Senioren im Quartier

Rupp K, Nebling T, Zastrau R, et al. NetzWerk LebenPlus (NWLP) - ein Hilfs- und Betreuungsnetzwerk für Senioren im Quartier. In: Amelung VE, Eble S, Hildebrandt H, et al., eds. Innovationsfonds - Impulse für das deutsche Gesundheitssystem. Berlin: MWV Medizinisch Wissenschaftliche Verlagsgesellschaft; 2017: 218-224